Tami L Mark

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5042750/publications.pdf

Version: 2024-02-01

1163117 1125743 13 336 8 13 citations h-index g-index papers 13 13 13 424 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	Opioid medication discontinuation and risk of adverse opioid-related health care events. Journal of Substance Abuse Treatment, 2019, 103, 58-63.	2.8	127
2	Insurance Financing Increased For Mental Health Conditions But Not For Substance Use Disorders, 1986–2014. Health Affairs, 2016, 35, 958-965.	5.2	54
3	For What Diagnoses Are Psychotropic Medications Being Prescribed?. CNS Drugs, 2010, 24, 319-326.	5.9	52
4	Association of Formulary Prior Authorization Policies With Buprenorphine-Naloxone Prescriptions and Hospital and Emergency Department Use Among Medicare Beneficiaries. JAMA Network Open, 2020, 3, e203132.	5.9	30
5	Psychiatric and medical comorbidities, associated pain, and health care utilization of patients prescribed buprenorphine. Journal of Substance Abuse Treatment, 2013, 44, 481-487.	2.8	24
6	Substance Use Disorders Among Medicare Beneficiaries: Prevalence, Mental and Physical Comorbidities, and Treatment Barriers. American Journal of Preventive Medicine, 2022, 63, 225-232.	3.0	12
7	Adherence to buprenorphine treatment guidelines among individuals with an opioid use disorder who have private insurance. Journal of Substance Abuse Treatment, 2020, 116, 108062.	2.8	9
8	Opioid Prescribing to Adolescents in the United States From 2005 to 2016. Psychiatric Services, 2018, 69, 1040-1043.	2.0	8
9	How to Mitigate the Mental Health Care Consequences of the COVID-19 Financial Crisis. Psychiatric Services, 2020, 71, 1317-1319.	2.0	7
10	What's in an "ASAM-based Assessment?―Variations in Assessment and Level of Care Determination in Systems Required to Use ASAM Patient Placement Criteria. Journal of Addiction Medicine, 2022, 16, 18-26.	2.6	5
11	Is implementation of ASAM-based addiction treatment assessments associated with improved 30-day retention and substance use?. Drug and Alcohol Dependence, 2021, 226, 108868.	3.2	4
12	The association of Medicare Part D prior authorization for buprenorphine–naloxone with adherence to opioid use disorder treatment guidelines in the United States. Addiction, 2022, 117, 141-150.	3.3	3
13	Receipt of Substance Use Disorder Treatment Among Patients Visiting Psychiatrists. Journal of Addiction Medicine, 2019, 13, 248-249.	2.6	1